Clinical trials: Transformed Migraine
Preventive Treatment of Migraine
A Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine
Rimegepant is a calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of migraine attacks in adults and for the preventive treatment of episodic migraine in adults when administered every…
- Trial name
- NCT07729462
- Testing
- Rimegepant
- Where
- 21 sites in United States, Israel
- Volunteers
- 400 people
- Sponsor
- Pfizer
Chronic Migraine
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
The main purpose of this study is to evaluate the efficacy of the study drug known as galcanezumab in participants with chronic migraine.
- Trial name
- REGAIN (NCT02614261)
- Testing
- Galcanezumab
- Where
- 117 sites in United States, Argentina and 11 more
- Volunteers
- 1,117 people
- Sponsor
- Eli Lilly and Company
Chronic Migraine, Headache
Open Label, 6-month Study for High Frequency and Chronic Migraine,
This is a prospective, multi-center, unblinded study in patients with migraine (≥ 8 MMDs/month) requiring preventive treatment. Enrolled patients will receive DAX administered subcutaneously using an established, published…
- Trial name
- NCT06133491
- Testing
- Daxibotulinumtonix A
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Ki Health Partners. LLC
Patients With Migraine Equal of /More Than 3 and Equal of/ Less Than 12 Migraine Attacks/4 Weeks for Each of the Last 6 Months Preceding the Screening
A Randomized,Double Blind, Placebo Controlled Study to Assess Efficacy,Safety and Tolerability of BGG492 in Migraine Prevention
It will provide a first evaluation of efficacy, safety and tolerability of BGG492 in patients with non-chronic migraine having more than 3 and less than 12 migraine attacks per 4 weeks.
- Trial name
- NCT01617941
- Testing
- BGG492
- Sponsor
- Novartis Pharmaceuticals
Chronic Migraine
Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine
Migraine is characterized by attacks of throbbing, moderate or severe headache, often associated with nausea, vomiting, and/or sensitivity to light and/or sound.
- Trial name
- ATO-BOTOX (NCT05216263)
- Testing
- Atogepant
- Where
- 29 sites in United States
- Volunteers
- 75 people
- Sponsor
- AbbVie
Chronic Migraine Headache
Occipital Nerve Stimulation for the Treatment of Chronic Migraine Headache.
Background: Medically intractable chronic migraine (CM) is a disabling illness characterized by headache greater than 15 days per month.
- Trial name
- ONSTIM (NCT00200109)
- Testing
- Occipital Nerve Stimulation
- Where
- 9 sites in United States, Canada and 1 more
- Volunteers
- 110 people
- Sponsor
- MedtronicNeuro
Migraine Disorders
Chronic Migraine Epidemiology and Outcomes Study
This is a population internet-based study to characterize migraine clinical course and impact on family.
- Trial name
- NCT01648530
- Testing
- No Treatment
- Volunteers
- 16,789 people
- Sponsor
- Allergan
Migraine
Study of Quality of Life in Subjects With Chronic or High-frequency Episodic Migraine and Associated Comorbidities Treated With Erenumab
Migraine is a very common, neurological disorder, characterized by recurrent episodes of headache, potential progression to more frequent and severe attack patterns, and associated symptoms.
- Trial name
- COMIG (NCT04114630)
- Testing
- erenumab 70mg/mL
- Where
- 27 sites in Spain
- Sponsor
- Novartis Pharmaceuticals
Migraine
Occipital Nerve Stimulation in the Treatment of Migraine
The objective of this proof-of-concept study is to generate initial safety and effectiveness data for the neuro-modulation stimulation (NMS) E-Box in patients with chronic migraine in an acute setting.
- Trial name
- Verona (NCT01855672)
- Testing
- Stimulation of the Occipital Nerves
- Where
- 4 sites in United States
- Volunteers
- 1 people
- Sponsor
- Ethicon, Inc.
Migraine Disorders
An Observational Study of BOTOX® as Headache Prophylaxis for Chronic Migraine
This is an observational study to describe the long term use of Onabotulinumtoxin A (BOTOX®) as prescribed by the physician for headache prophylaxis in adults with chronic migraine. All treatment decisions lie with the physician.
- Trial name
- NCT01686581
- Testing
- botulinum toxin Type A
- Where
- 77 sites in Germany, Italy and 5 more
- Volunteers
- 641 people
- Sponsor
- Allergan
Chronic Migraine
Efficacy and Safety of Nerivio™ for Acute Treatment of Migraine in People With Chronic Migraine
This study is intended to evaluate the efficacy and safety of Nerivio, an FDA-authorized remote electrical neuromodulation (REN) device for the acute treatment of migraine, for the acute treatment of migraine in people with…
- Trial name
- NCT04161807
- Testing
- Nerivio
- Where
- 2 sites in United States, Israel
- Volunteers
- 42 people
- Sponsor
- Theranica
Migraine, Headache
Evaluation of the Effectiveness of Topiramate in Preventing the Transformation From Episodic Migraine to Chronic Daily Headache.
The purpose of this study is to determine whether Topiramate is effective in preventing the development of chronic daily headache among patients with episodic migraine headaches.
- Conditions
- Migraine, Headache, Classic Migraine, Common Migraine
- Trial name
- NCT00212810
- Testing
- Topiramate
- Volunteers
- 385 people
- Sponsor
- Ortho-McNeil Neurologics, Inc.
Chronic Migraine
Use of the Tx360 Nasal Applicator in the Treatment of Chronic Migraine
Migraine imposes a substantial burden on patients in terms of diminished daily functioning, quality of life, and financial loss.
- Trial name
- Tx360 (NCT01709708)
- Testing
- Marcaine, Saline
- Where
- 2 sites in United States
- Volunteers
- 41 people
- Sponsor
- Tian Medical Inc.
Episodic Migraine, Chronic Migraine
A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine
This study will evaluate the Long-Term Safety and Tolerability of Atogepant 60 mg daily for the Prevention of Migraine in Participants with Chronic or Episodic Migraine
- Trial name
- NCT04686136
- Testing
- Atogepant 60 mg
- Where
- 116 sites in United States, Canada and 12 more
- Volunteers
- 596 people
- Sponsor
- AbbVie
Migraine
The Effectiveness and Safety of Topiramate on Prevention of Chronic Migraine
The purpose of this study is to evaluate the safety and effectiveness of individualized doses (50 to 200 milligrams) of topiramate tablets compared against placebo for the prevention of chronic migraine headaches over a period of…
- Trial name
- NCT00216606
- Testing
- topiramate
- Volunteers
- 59 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Chronic Migraine in Children
A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine
To find out if eptinezumab is better than placebo (normal saline solution) in lowering the number of days with migraine in young people ages 12 to 17 with chronic migraine.
- Trial name
- PROSPECT-2 (NCT04965675)
- Testing
- Eptinezumab
- Where
- 79 sites in United States, Argentina and 9 more
- Volunteers
- 285 people
- Sponsor
- H. Lundbeck A/S
Chronic Migraine
Efficacy and Safety of Nerivio Device for Acute Treatment of Migraine in People With Chronic Migraine
A prospective, single arm, open-label, multicenter trial to assess the efficacy and safety of the Nerivio device in chronic migraine patients.
- Trial name
- NCT04194008
- Testing
- Nerivio
- Where
- 10 sites in United States
- Volunteers
- 126 people
- Sponsor
- Theranica
Migraine, Chronic Migraine
Eptinezumab as an Adjunct to Standard of Care for Migraine in an Acute Emergency Context
The purpose of the study is to investigate how a medication called eptinezumab (Vyepti) given to patients in the Emergency Department (ED) might help prevent migraines from happening again.
- Trial name
- NCT06428838
- Testing
- Eptinezumab, Standard of Care
- Where
- 2 sites in Canada
- Volunteers
- 102 people
- Sponsor
- Dr George Medvedev
Chronic Migraine, Headache
Adjunctive Treatment of Chronic Migraine Using an Oral Dental Device
Single blinding study comparing FDA cleared device for prevention of medically diagnosed migraine pain to placebo.
- Trial name
- NCT04871581
- Testing
- NTI-tss
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- ChairsideSplint.com
Migraine
A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments
The purpose of this trial is to determine which doses of Lu AG09222 are recommended to help prevent migraines. People who join this trial have already tried 1 to 4 other available medications to prevent their migraines, but these…
- Trial name
- PROCEED (NCT06323928)
- Testing
- Lu AG09222
- Where
- 120 sites in United States, Bulgaria and 12 more
- Volunteers
- 874 people
- Sponsor
- H. Lundbeck A/S